

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2017		2. REPORT TYPE Annual Report		3. DATES COVERED 30 Sep 2016 - 29 Sep 2017	
4. TITLE AND SUBTITLE Development of a PET Prostate-Specific Membrane Antigen Imaging Agent: Preclinical Translation for Future Clinical Application				5a. CONTRACT NUMBER W81XWH-14-1-0603	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Henry VanBrocklin E-Mail: henry.vanbrocklin@ucsf.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, San Francisco 1855 Folsom St Ste 425 San Francisco CA 94103-4249				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND (expIND; phase 0) application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen (PSMA) that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.					
15. SUBJECT TERMS Prostate Cancer, Prostate Specific Membrane Antigen (PSMA), Fluorine-18, Molecular Imaging, Radiotracer, Automated Synthesis, Phosphoramidate, Inhibitor, Peptide Mimic, Peptidomimetic					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	19	19b. TELEPHONE NUMBER (include area code)

Table of Contents

1. Introduction	3
2. Keywords	3
3. Accomplishments	3
4. Impact	10
5. Changes/ Problems	10
6. Products	11
7. Participants and other collaborating organizations	12
8. Special Reporting Requirements	14
9. Appendices	14
A. Quad Chart	15

1. INTRODUCTION:

The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND (expIND; phase 0) application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen (PSMA) that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.

2. KEYWORDS:

Prostate Cancer, Prostate Specific Membrane Antigen (PSMA), Fluorine-18, Molecular Imaging, Radiotracer, Automated Synthesis, Phosphoramidate, Inhibitor, Peptide Mimic, Peptidomimetic

3. ACCOMPLISHMENTS:

What were the major goals and objectives of the project?

Aim 1: Prepare non-radioactive precursor phosphoramidate PSMA targeting molecules and their corresponding fluorobenzamide analogs. Perform radiochemistry to form [¹⁸F]fluorobenzamide – phosphoramidate peptidomimetics. Optimize the synthesis of the [¹⁸F]fluorobenzamide coupling.

Task 1.1: Prepare the non-radioactive phosphoramidate labeling precursors

Task 1.2: Prepare the non-radioactive fluorobenzamido-phosphoramidate standard compounds

Task 1.3: Radiolabel the precursor phosphoramidates with [¹⁸F]succinimidyl fluorobenzoate.

Task 1.4: Optimize [¹⁸F]succinimidyl fluorobenzoate labeling of the phosphoramidates.

Task 1.5: Explore solid phase extraction for purification (SPE) of the fluorobenzamido-phosphoramidates

Aim 2: Determine pharmacokinetic and toxicologic properties of the fluorobenzamidophosphoramidates

Task 2.1: Obtain DoD animal approval for the imaging and metabolism studies

Task 2.2: Biodistribution studies of the two [¹⁸F]fluorobenzamido-phosphoramidates

Task 2.3: Obtain DoD approval for the toxicology studies

Task 2.4: Radiotracer Stability studies

Task 2.5: Radiotracer *in vivo* metabolism studies

Task 2.6: Radiotracer Dosimetry studies

Task 2.7: Toxicity evaluation

Aim 3: Collect final data for the submission of the exploratory IND to the FDA

Task 3.1: Automate the [¹⁸F]fluorobenzamido-phosphoramidate synthesis on the Neptis® synthesis unit.

Task 3.2: Prepare SOPs and batch record Documents for the radiosynthesis

Task 3.3: Human Studies Protocol for submission to UCSF IRBs

Task 3.4: Final radiosynthesis validation runs with full Quality Control analysis

Task 3.5: Complete the exploratory IND for FDA submission


Task 3.6: Submit IND to FDA, Respond to FDA Questions

Task 3.7: DoD Final Report


What was accomplished under these goals?

Task 1.1: Prepare the non-radioactive phosphoramidate labeling precursors.


A focus was made on the synthesis of larger quantities of AH2-TG97 (as well as AH-TG97) in preparation for scale-up for toxicity studies. Methods have been optimized to improve yields as shown in the **Schemes 1** and **2** below.



Scheme 1. Optimized synthesis of the radiolabeling precursors AH-TG97 and AH2-TG97.




Scheme 2a. Optimized synthesis of the radiolabeling precursor AH-TG97




Scheme 2b. Optimized synthesis of the radiolabeling precursors AH₂-TG97.

Task 1.2: Prepare the non-radioactive fluorobenzamido-phosphoramidate standard compounds.

Non-radioactive standards of FB-AH-TG97 and FB-AH₂-TG97 were prepared as proposed in Scheme 3. The method to prepare and purify ¹⁹F-fluorobenzyl-AH-TG97 (FB-AH-TG97) was slightly modified to improve the coupling yield. Specifically, the coupling step with SFB and AH-TG97 was performed in potassium phosphate buffer (0.5 M, pH 7.5). The product was purified using G-10 size-exclusion chromatography resulting in 94.5% purity (254 nm); HPLC trace shown below.



Scheme 3. Coupling step from radiolabeling precursors (AH-TG97 and AH₂-TG97) to the radioactive and non-radioactive final products ^{18/19}FB-AH-TG97 and ^{18/19}FB-AH₂-TG97.



Task 1.3: Radiolabel the precursor phosphoramidates with [^{18}F]succinimidyl fluorobenzoate.

Completed in Year 1

Task 1.4: Optimize [^{18}F]succinimidyl fluorobenzoate labeling of the phosphoramidates.



Figure 3. Elixys synthesis unit that has been programmed to prepare SFB and label the AH-TG97 precursors.

^{18}F -AH-TG97 optimization was completed in Year 1 and labeling parameters for the reproducible preparation of the ^{18}F -AH-TG97 on the NEPTIS automated synthesis unit were determined (Task 3.1). We revisited the optimization of the ^{18}F -AH-TG97 and ^{18}F -AH2-TG97 in an attempt to increase the overall yield of the final product. We programmed the Sofie Biosciences Elixys synthesis unit, pictured in Figure 3, to prepare [^{18}F]succinimidyl fluorobenzoate (SFB) for coupling with AH-TG97 and AH2-TG97. Modifications to the synthesis of SFB including potassium carbonate/ kryptofix for the ^{18}F -fluoride ion incorporation and added TSTU for the formation of the imidazole did not significantly improve yield. Optimization of the SFB coupling to the TG97 precursors including adjusting solvent volumes, concentration, reaction times, buffer and pH are ongoing. Initial studies revealed that solvent volume and ratio of acetonitrile to water impact the SFB coupling yields to give the final products.

Task 1.5: Explore solid phase extraction (SPE) for purification of the fluorobenzamido-phosphoramidates

Solid phase extraction (SPE) for ^{18}F -AH-TG97 was completed in Year 1. We revisited the SPE for AH2-TG97 during year 3. We evaluated changing solvent strengths for the purification steps to separate the precursor AH2-T97 from ^{18}F -AH2-TG97. To date the separation remains incomplete. This work is in progress and will be completed in year 4.

Task 2.1: Obtain DoD animal approval for the imaging and metabolism studies

Final approval of the ACURO for preclinical imaging and metabolism was obtained.

Task 2.2: Biodistribution studies of the two [^{18}F]fluorobenzamido-phosphoramidates

To be completed upon animal approval (Task 2.1)

Task 2.3: Obtain DoD approval for the toxicology studies

Submission of the ACURO was completed. All questions have been addressed and final review of the ACURO document is in progress. Contracting with MPI the CRO that will conduct the toxicology studies was initiated and is ongoing.

Task 2.4: Radiotracer Stability studies

During requalification of the ^{18}F -AH-TG97 the stability was evaluated at 8 hours post preparation. The stability data is shown in Table 1. The current expiration of the batch has been established at 8 hours post manufacturing.

Table 1: 8 hour stability data for ^{18}F -AH-TG97

Quality Control Test and Specifications of ^{18}F-AH-TG97		
Stability – 8 Hours		
Test	Specification	170201FCTT
Appearance	Colorless/free from particles	Colorless/free from particles
Radiochemical purity	>85%	92%
Radiochemical Identity	RRT = 100 ± 0.05 as standard	0.96
Radionuclidic purity	511 keV peak must be present	511 keV present
Radionuclidic Identity	107 m < half life < 112.4 m ^{18}F half-life (109.7minutes)	108 min
Specific Activity	$\geq 500\text{Ci/mmol}$ (18.5 TBq/umol) (NLT 07 mCi/ μg)	680 Ci/mmol (0.96 mCi/ μg)
pH	4.5 – 7.5	5.5

Task 2.5: Radiotracer *in vivo* metabolism studies

In progress (Task 2.1)

Task 2.6: Radiotracer Dosimetry studies

The radiation dosimetry studies for ^{18}F -AH-TG97 and ^{18}F -AH2-TG97 were initiated. Tracer was prepared and injected into Sprage-Dawley male rats. The time course of distribution was followed by imaging using the Siemens InVeon microPET/CT. The tracer concentration in each organ will be calculated from time activity curves generated from the images. The area under the curves will be entered into OLINDA (radiation dosimetry software) and the whole body and organ dosimetry will be determined. As

seen in Figure 4, the distribution in male rats shown the uptake and clearance from the kidney through the bladder. This activity clears from the body over the 6h study. There appears to be some intestinal uptake that also rapidly clears over the course of the study.




Figure 4. Temporal distribution of radiotracer in normal Sprague-Dawley rats.

Task 2.7: Toxicity evaluation

Contracting with MPI the CRO that will conduct the toxicology studies was initiated and is ongoing. (Task 2.3)

Task 3.1: Automate the [¹⁸F]fluorobenzamido-phosphoramidate synthesis on the Neptis® synthesis unit.

We previously translated the synthesis of ¹⁸FB-AH-TG97/ AH2-TG97 with SPE purification to the NEPTIS® automated synthesis unit in the UCSF Radiopharmaceutical facility. The schematic diagram of the reagent setup with the cassettes and reagents in place is shown in Figure 5. The inset is the original SPE purification pathway where all of the materials and solvents went through the environmental C18. The new approach, shown in the full cassette, has a 3-way valve before and after the environmental C18 cartridge (red). This allows us to load the C18 column and then rinse it to waste before eluting the product onto the quaternary ammonium (QMA) cartridge (light blue). Then the C18 is bypassed and the final product is eluted with saline from the QMA without going through the C18 cartridge as was previously done. This process is more efficient and eliminates cleaning the C18 cartridge completely before eluting the tracer from the QMA. It also reduces residual solvent issues and eliminates small byproducts in the final preparation.




Figure 5. Schematic diagram showing the placement of reagents in the cassettes on the face of the Neptis synthesis unit.

Task 3.2: Prepare SOPs and batch record documents for the radiosynthesis

Completed in year 2.

Task 3.3: Human Studies Protocol for submission to UCSF IRBs

Completed in year 2

Task 3.4: Final radiosynthesis validation runs with full Quality Control analysis

Completed in year 2

Task 3.5: Complete the exploratory IND for FDA submission

Completed in year 2

Task 3.6: Submit IND to FDA, Respond to FDA Questions

Complete for ^{18}F B-AH-TG97 in year 2.

What opportunities for training and professional development has the project provided?

The UCSF postdoctoral fellow on this project, Dr. Kiel Neumann, gained significant practical knowledge about the preparation of radiopharmaceuticals and their translation for human use. The process of taking a labeled product from the laboratory to the clinic offer many opportunities to learn about the manufacturing and regulatory aspects of the process. He was instrumental in preparation of the Chemistry, Manufacturing and Control section of the FDA IND application and assisted in responding to the FDA questions. Dr. Neumann completed his postdoctoral fellowship in March 2017 and started his career as a faculty member in the Department of Radiology at the University of Virginia. He is currently working on the finishing a paper related to the automation of the ^{18}F B-TG97. Dr. Thomas Hayes started as a postdoctoral fellow in late June 2017. He had not performed tracer development with short-lived positron emitting radioisotopes before

joining UCSF. He has been a quick study and automated the tracer synthesis on the Elixys so that he could begin to further improve the tracer production while preparing doses for the preclinical studies.

How were the results disseminated to the communities of interest?

A manuscript entitled "Automated Syntheses Towards Clinical Production of the PSMA Imaging Agent [¹⁸F]CTT1057" is in preparation.

"Fully automated preparation of [¹⁸F]CTT1057, a new prostate cancer imaging agent, prepared using the ORA Neptis Perform Synthesizer®". J. Labelled Comp. Radiopharm, 60(suppl1), S297, 2017. Abstract presented at the 22th International Symposium on Radiopharmaceutical Sciences, Dresden Germany, May 2017.

What do you plan to do during the next reporting period to accomplish the goals?

Over this final funding/ reporting period we will complete all of the remaining tasks in this project. Major tasks include evaluation of the tracer dosimetry, tumor uptake and metabolism in mice. The toxicologic evaluation in rats will be completed with MPI research. This will necessitate the preparation of non-radioactive FB-AH2-TG97 by our collaborator Cliff Berkman at WSU. Further optimization of the automated preparation of the racers will be performed concomitant with the preparation of the tracers for the preclinical studies. A final report of all activities will be written.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

It is anticipated that the radiotracers being advanced to clinical trials will replace the current clinically available radiotracer Proscint for PSMA imaging in prostate cancer. Proscint is a mouse antibody that homes to a binding site on the PSMA that is inside of the cancer cells. The antibody is a large molecule (~300 times the weight) compared to the current compounds being developed in this proposal. Proscint has a difficult time crossing the intact cell membrane to bind to its target. The molecules in this proposal bind to a site on the PSMA protein on the outside of the cancer cell making the interaction more feasible. Successful application of the new tracers will have a fill a significant unmet need for a PSMA imaging agent and provide a means of staging disease and monitoring treatment. Additionally, other solid tumors including renal cell carcinoma and hepatocellular carcinoma express PSMA. The agents developed herein may also be used to visualize tumor and metastatic tissue.

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

The new diagnostic imaging agents will benefit those suffering from prostate cancer by offering important information that will inform therapy and monitor disease progression and remission.

5. Changes/Problems:

Changes in approach and reasons for change

Nothing to report

Actual or anticipated problems or delays and action or plans to resolve them

Postdoctoral fellow change delayed completion of the final tasks over the past year. There was a gap in postdoctoral fellow coverage for this grant from March to June 2017.

Changes that had a significant impact on expenditures

Nothing to Report

Significant changes in use of care of human subjects, vertebrate animals, biohazards and/or select agents

Nothing to Report

6. PRODUCTS:

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Henry VanBrocklin PI 4</p> <p>Dr. VanBrocklin oversaw and directed the research studies under this project. He coordinated efforts with Dr. Cliff Berkman at Washington State University (subcontract). He completed the ACURO for the toxicology studies. He coordinated the activities of the postdoctoral fellows, Drs. Neumann and Hayes. He reviewed and analyzed all of the data and prepared the annual report.</p> <p>FDA U01, NIH U01, 2 NIH R21s, 2 NIH R01s, 2 NIH SBIRs, 1 NIH UM1</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Joseph Blecha Research Associate 2</p> <p>Mr. Blecha performed radiosynthesis and purification of PSMA agents</p> <p>NIH R01, NIH U01, FDA U01</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Kiel Neumann Postdoctoral Fellow 3</p> <p>Dr. Neumann developed the assay for the precursor in the final product solution. He optimized the radiochemistry for translation to the NEPTIS® unit. He developed the SPE purification. He developed the HPLC methods for purification and analysis of the tracer</p> <p>NIH U01</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Thomas Hayes Postdoctoral Fellow 2</p> <p>Dr. Hayes automated the radiotracer synthesis in the Elixys synthesis unit. He prepared tracers for preclinical studies.</p> <p>NIH U01</p>

<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Spencer Behr Co-Investigator 0.3</p> <p>Dr. Behr contributed to the development of the protocol for the first-in-human imaging study submitted to the IRB</p> <p>NIH SBIR, Clinical Support</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Salma Jivan Research Associate 2</p> <p>Translated the radiotracer synthesis to the Neptic Automated Synthesis Unit. She developed the Batch Record and SOPs for the synthesis and quality control. She performed the synthesis of the 3 qualification batches and collected the data for the CMC section of the IND.</p> <p>Departmental and Clinical Support</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Clifford Berkman Washington State Univ Subcontract PI 2</p> <p>Dr. Berkman has overseen the synthesis and analytical work on the radiolabeling precursors and authentic standards, as well as transferring non-radioactive methods to the Dr. VanBrocklin's lab. He has also facilitated the transfer of precursor material to Dr. VanBrocklin's lab for the laboratory and automation preparation of the tracers. He worked with Dr. VanBrocklin on the data analysis and preparation of this report.</p> <p>NIH R21 and DoD</p>
<p>Name: Project Role: Nearest person month worked:</p> <p>Contribution to Project:</p> <p>Funding support:</p>	<p>Cindy Choy Research Assistant Professor 2</p> <p>Dr. Choi conducted synthesis and analytical work on the radiolabeling precursors and authentic standards. She also oversaw the training of 2 undergraduate students and 2 graduate students.</p> <p>DoD</p>

8. SPECIAL REPORTING REQUIREMENTS: None

9. APPENDICES:

A. QUAD CHART

Development of a PET Prostate-Specific Membrane Antigen Imaging Agent: Preclinical Translation for Future Clinical Application



W81XWH-14-1-0603 (PC130431)

PI: Henry F. VanBrocklin, Ph.D.

Org: University of California San Francisco


Award Amount: \$1,421,999

Study/Product Aim(s)

- **Aim 1:** Prepare non-radioactive precursor phosphoramidate PSMA targeting molecules and their corresponding fluorobenzamide analogs.
- **Aim 2:** Determine pharmacokinetic and toxicologic properties of the fluorobenzamidophosphoramidates
- **Aim 3:** Collect final data for the submission of the exploratory IND to the FDA

Approach

The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18 for diagnosis and monitoring of prostate cancer. These data will enable the filing of an exploratory IND (expIND; phase 0) application to the FDA by the end of the funding period.



Pharmacokinetic evaluation of ¹⁸F-BH2-TG97 in normal male Sprague-Dawley rats. Normal distribution and clearance of the imaging agent is seen. The tracer clears mainly through the kidneys and bladder. Some gut uptake is noted. Images from InVeo microPET/CT.

Timeline and Cost

Activities	FY	15	16	17	18
Aim 1 Synthesis					
Aim 2 Preclinical Assessment					
Aim 3 Automate Prep/IND CMC Data					
Estimated Budget (\$K)		\$735	\$667	NCE	NCE

Updated: 10/30/17

Key Research Accomplishments

- Prepared FB-AH2-TG97 (non-radioactive) for toxicology studies
- Fully automated the synthesis of ¹⁸F-BH-AH-TG97/ AH-TG97 on the Elixys synthesis unit
- Completed ACURO for toxicology studies
- Determined stability to 8h for ¹⁸F-BH-AH-TG97
- Initiated imaging studies for dosimetry calculation
- Continued to optimize synthesis to increase production yields